- Home
- NRO vs CRVS Comparison
NRO vs CRVS Comparison
Compare NRO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CRVS
- Stock Information
- Founded
- NRO 2003
- CRVS 2014
- Country
- NRO United States
- CRVS United States
- Employees
- NRO N/A
- CRVS N/A
- Industry
- NRO Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- CRVS Health Care
- Exchange
- NRO Nasdaq
- CRVS Nasdaq
- Market Cap
- NRO 187.8M
- CRVS 516.0M
- IPO Year
- NRO N/A
- CRVS 2016
- Fundamental
- Price
- NRO $3.50
- CRVS $5.10
- Analyst Decision
- NRO
- CRVS Strong Buy
- Analyst Count
- NRO 0
- CRVS 5
- Target Price
- NRO N/A
- CRVS $12.38
- AVG Volume (30 Days)
- NRO 239.4K
- CRVS 1.7M
- Earning Date
- NRO 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- NRO 11.41%
- CRVS N/A
- EPS Growth
- NRO N/A
- CRVS N/A
- EPS
- NRO N/A
- CRVS N/A
- Revenue
- NRO N/A
- CRVS N/A
- Revenue This Year
- NRO N/A
- CRVS N/A
- Revenue Next Year
- NRO N/A
- CRVS N/A
- P/E Ratio
- NRO N/A
- CRVS N/A
- Revenue Growth
- NRO N/A
- CRVS N/A
- 52 Week Low
- NRO $2.51
- CRVS $1.30
- 52 Week High
- NRO $3.45
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NRO 42.49
- CRVS 36.16
- Support Level
- NRO $3.52
- CRVS $4.93
- Resistance Level
- NRO $3.62
- CRVS $6.47
- Average True Range (ATR)
- NRO 0.08
- CRVS 0.40
- MACD
- NRO 0.01
- CRVS 0.06
- Stochastic Oscillator
- NRO 40.00
- CRVS 29.74
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).